Abstract: A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:

Abstract: A blood flow field estimation apparatus is provided, including an estimation unit that uses a learned model obtained in advance by performing machine learning to learn a relationship between organ tissue three-dimensional structure data including image data of a plurality of organ cross-sectional images serving as cross-sectional images of an organ and having each pixel provided with two or more bit depths and image position information serving as information indicating a position of an image reflected on each of the organ cross-sectional images in the organ, and a blood flow field in the organ, and estimates the blood flow field in the organ of an estimation target, based on the organ tissue three-dimensional structure data of the organ of the estimation target, and an output unit that outputs an estimation result of the estimation unit.

Abstract: An object is to provide a cell product for treating and/or preventing vascular dementia. The present invention provides a cell product for treating or preventing vascular dementia, containing a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.

Abstract: A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: The present invention discloses a method for administering SN-38-loaded polymeric micelles into the central nervous system of a human subject via a convection-enhanced delivery system. The convection-enhanced delivery is achieved by using an osmotic pump or an infusion pump. Further, SN-38-loaded polymeric micelles are administered into a target region of the brain of the subject.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: An object of the present invention is to provide a composite material that may be easily delivered and mounted in the living body. The object can be solved by a coated composite material characterized in that a composite material, in which a porous body is bounded to a substrate, is coated with at least one soluble component selected from a group consisting of a water-soluble compound, a temperature-sensitive soluble compound, and a pH sensitive soluble compound.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: The present invention discloses a method for administering SN-38-loaded polymeric micelles into the central nervous system of a human subject via a convection-enhanced delivery system. The convection-enhanced delivery is achieved by using an osmotic pump or an infusion pump. Further, SN-38-loaded polymeric micelles are administered into a target region of the brain of the subject.

Abstract: A jet stream generating device that generates a jet stream of liquid includes: a cylindrical liquid chamber; a nozzle configured to open an end part of the liquid chamber and inject liquid F in the liquid chamber to outside; a liquid supply path configured to supply liquid F into the liquid chamber; a laser beam irradiation part configured to irradiate a pulse laser beam into the liquid chamber, and vaporize the liquid F in the liquid chamber; and a laser oscillator configured to control laser beam intensity and laser beam pulse width independently. An inner surface of the liquid chamber has a mirror plane for reflecting and guiding the pulse laser beam emitted from the laser beam irradiation part to the end part of the liquid chamber, and an adjusting part configured to adjust a distance between the nozzle and the laser beam irradiation part is included.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: A jet stream generating device that generates a jet stream of liquid includes: a cylindrical liquid chamber; a nozzle configured to open an end part of the liquid chamber and inject liquid F in the liquid chamber to outside; a liquid supply path configured to supply liquid F into the liquid chamber; a laser beam irradiation part configured to irradiate a pulse laser beam into the liquid chamber, and vaporize the liquid F in the liquid chamber; and a laser oscillator configured to control laser beam intensity and laser beam pulse width independently. An inner surface of the liquid chamber has a mirror plane for reflecting and guiding the pulse laser beam emitted from the laser beam irradiation part to the end part of the liquid chamber, and an adjusting part configured to adjust a distance between the nozzle and the laser beam irradiation part is included.

Abstract: A liquid ejection device that suppresses scatter of the living tissue, such as cells excised, fragmentated, or otherwise separated by ejected pulsed flow is provided. The liquid ejection device ejects, through a nozzle 4, first liquid 12 in the form of pulses supplied through an ejection tube 3 and includes a supply tube 23, through which second liquid 31 is supplied to a region in the vicinity of the nozzle 4. The liquid ejection device further includes a suction port 15, which is located in the vicinity of the nozzle 4, and a suction pump 18, which is connected to the suction port 15 via a suction tube 14 and sucks the first liquid 12 and the second liquid 31.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Abstract: Occlusion of a blood vessel is improved by a medical treatment system including a ejection device that includes an insertion section insertable into a tissue of an animal and is capable of ejecting first liquid as a pulsating flow from a distal end of the insertion section and a control apparatus configured to bring the distal end of the insertion section close to a blood vessel in the tissue, which is a medical treatment target, and eject the first liquid as the pulsating flow from the distal end of the insertion section in a state in which second liquid is interposed in a region covering the blood vessel.